4TUH

Bcl-xL in complex with inhibitor (Compound 10)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.172 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Koehler, M.F.Bergeron, P.Choo, E.F.Lau, K.Ndubaku, C.Dudley, D.Gibbons, P.Sleebs, B.E.Rye, C.S.Nikolakopoulos, G.Bui, C.Kulasegaram, S.Kersten, W.J.Smith, B.J.Czabotar, P.E.Colman, P.M.Huang, D.C.Baell, J.B.Watson, K.G.Hasvold, L.Tao, Z.F.Wang, L.Souers, A.J.Elmore, S.W.Flygare, J.A.Fairbrother, W.J.Lessene, G.

(2014) Acs Med.Chem.Lett. 5: 662-667

  • DOI: 10.1021/ml500030p

  • PubMed Abstract: 
  • Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, pote ...

    Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.


    Organizational Affiliation

    AbbVie, Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064, United States.,Walter and Eliza Hall Institute of Medical Research , 1G Royal Parade, Parkville, VIC 3052, Australia ; Department of Medical Biology, The University of Melbourne , Parkville, Victoria, Australia.,Departments of Discovery Chemistry, Drug Metabolism and Pharmacokinetics, and Early Discovery Biochemistry, Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Bcl-2-like protein 1
A, B, C, D, E, F, G, H
158Homo sapiensMutation(s): 0 
Gene Names: BCL2L1 (BCL2L, BCLX)
Find proteins for Q07817 (Homo sapiens)
Go to Gene View: BCL2L1
Go to UniProtKB:  Q07817
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ACT
Query on ACT

Download SDF File 
Download CCD File 
B
ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M
 Ligand Interaction
EDO
Query on EDO

Download SDF File 
Download CCD File 
A, C, F, G, H
1,2-ETHANEDIOL
ETHYLENE GLYCOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
38H
Query on 38H

Download SDF File 
Download CCD File 
A, B, C, D, E, F, G, H
2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-{3-[4-(1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenoxy]propyl}-1,3-thiazole-4-carboxylic acid
C35 H28 N8 O4 S2
LMOJCFKMCAPGGY-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.172 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 59.834α = 90.00
b = 109.661β = 91.77
c = 102.099γ = 90.00
Software Package:
Software NamePurpose
PHENIXrefinement
Cootmodel building
Blu-Icedata collection
PDB_EXTRACTdata extraction
SCALEPACKdata scaling
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2014-10-15
    Type: Initial release
  • Version 1.1: 2017-11-22
    Type: Data collection, Derived calculations, Other, Refinement description, Source and taxonomy